Bornfeldt KE, Tabas I (2011) Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14:575–585
Article CAS PubMed PubMed Central Google Scholar
Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB (2012) Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 18:721–726
Cubbon RM, Rajwani A, Wheatcroft SB (2007) The impact of insulin resistance on endothelial function, progenitor cells and repair. Diab Vasc Dis Res 4:103–111
Durante W, Behnammanesh G, Peyton KJ (2021) Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int J Mol Sci. 22(16):8786
Article CAS PubMed PubMed Central Google Scholar
Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S (2003) Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 123:2007–2011
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality. from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234
Article CAS PubMed Google Scholar
Han Y, Cho YE, Ayon R, Guo R, Youssef KD, Pan M, Dai A, Yuan JX, Makino A (2015) SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol. 309(9):L1027-1036
Article CAS PubMed PubMed Central Google Scholar
Hu WS, Lin CL (2018) Use of the progression of adapted Diabetes Complications Severity Index to predict acute coronary syndrome, ischemic stroke, and mortality in Asian patients with type 2 diabetes mellitus: a nationwide cohort investigation. Clin Cardiol 41(8):1038–1043
Article PubMed PubMed Central Google Scholar
Hu WS, Lin CL (2024) Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study. Naunyn Schmiedebergs Arch Pharmacol. 397(1):575–581
Article CAS PubMed Google Scholar
Hu WS, Hsieh MH, Lin CL (2018) Comparisons of changes in the adapted diabetes complications severity index and CHA2DS2-VASc score for atrial fibrillation risk stratification in patients with type 2 diabetes mellitus: a nationwide cohort study. Int J Cardiol. 15(269):122–125
Huang D, Ju F, Du L, Liu T, Zuo Y, Abbott GW, Hu Z (2022) Empagliflozin protects against pulmonary ischemia/reperfusion injury via an ERK1/2-dependent mechanism. J Pharmacol Exp Ther. 380(3):230–231
Article CAS PubMed Google Scholar
Jeong HE, Park S, Noh Y, Bea S, Filion KB, Yu OHY, Jang SH, Cho YM, Yon DK, Shin JY (2023) Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study. BMC Med. 21(1):47
Article CAS PubMed PubMed Central Google Scholar
Kim JA, Montagnani M, Koh KK, Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction. Mol Pathophysiol Mech Circ 113:1888–1904
Kolahian S, Leiss V, Nürnberg B (2019) Diabetic lung disease: fact or fiction? Rev Endocr Metab Disord. 20:303–319
Article CAS PubMed PubMed Central Google Scholar
Kopf S, Groener JB, Kender Z, Fleming T, Brune M, Riedinger C, Volk N, Herpel E, Pesta D, Szendrödi J, Wielpütz MO, Kauczor HU, Katus HA, Kreuter M, Nawroth PP (2018) Breathlessness and restrictive lung disease: an important diabetes-related feature in patients with type 2 diabetes. Respiration. 96:29–40
Liang CP, Han S, Senokuchi T, Tall AR (2007) The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res 100:1546–1555
Article CAS PubMed Google Scholar
McMurray JJV, De Mets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD (2019) DAPA-HF Committees and Investigators. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail. 21(5):665–675. https://doi.org/10.1002/ejhf.1432
Article CAS PubMed Google Scholar
National Health Research Institutes. National Health Insurance Research Database. http://nhird.nhri.org.tw/en/index.html. Accessed 14 Apr 2015
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F (2020) EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 383(15):1413–1424
Article CAS PubMed Google Scholar
Rabar S, Harker M, O’Flynn N, Wierzbicki AS (2014) Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 349:g4356–g4356
Rajasurya V, Gunasekaran K, Surani S (2020) Interstitial lung disease and diabetes. World J Diabetes. 11(8):351–357
Article PubMed PubMed Central Google Scholar
Stone NJ, Robinson JG, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 63(25 pt B):2889–2934
Wijsenbeek M, Suzuki A, Maher TM (2022) Interstitial lung diseases. Lancet. 400(10354):769–786
Young BA, Lin E, Von Korff M et al (2008) Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 14:15–23
留言 (0)